ESR1 and metastatic neoplasm: Thus, both the IPA analysis and our finding that these factors maintain associations in the high impact group, and metastatic tumors suggest that combination therapies that include ER, MEK, JNK, and/or ERK inhibitors may provide some benefit to patients undergoing ADT.